Privi Speciality Chemicals Limited · NSE:PRIVISCL
Privi Speciality Chemicals — Q2 FY27 Earnings Presentation
25 slides from Privi Speciality Chemicals's earnings presentation, Oct 30, 2026
Slide 1: Cover letter to BSE and NSE
October 30, 2026 The Manager (CRD) The Manager – Listing Department The BSE Limited National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Fort, Bandra-Kurla Complex, Bandra (East) Mumbai- 400001 Mumbai - 400 051 Scrip Code: 530117 Symbol
Slide 2: Investor Presentation Q2 & H1 FY26-27
Investor Presentation Q2 & H1 FY26-27 We d o d i ffe re nt t hi ng s, We d o t hi ng s d i ffe re nt l y Prosperity With Orderliness
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Privi Speciality Chemicals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe fo
Slide 4: Index
Index 01 02 Highlight’s Q2 & H1 FY27 Results Strategic vision and performance overview Consolidated performance metrics 03 04 Company Overview Growth Strategy About Us Strategic priorities and outlook Prosperity With Orderliness
Slide 5: Highlights
Highlights ▪ Q2 FY27 extended our momentum with strong financial performance, reflecting the resilience of our business model and disciplined execution even under difficult global headwinds. ▪ We delivered Rs 773.16 Cr of total income representing 13.90% year-on-year growth, Rs 212.49 Cr of EBITDA w
Slide 6: Performance at a glance – Q2 & H1 FY27
Performance at a glance – Q2 & H1 FY27 Q2 FY27 Revenue (Rs. Cr) EBITDA (Rs. Cr) EBITDA Margin (%) PAT (Rs. Cr) 773.16 212.49 27.48% 117.03 (+13.9% YoY) (+16.7% YoY) (+65 bps YoY) (+24.6% YoY) H1 FY27 Revenue (Rs. Cr) EBITDA (Rs. Cr) EBITDA Margin (%) PAT (Rs. Cr) 1,454.59 379.96 26.12% 201.23 (+16.7
Slide 7: Consolidated Profit & Loss Account
Consolidated Profit & Loss Account Particulars (Rs. Cr.) Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YoY FY26 Revenue from operations 760.45 678.71 1,426.67 1,237.53 2,563.69 Other income 12.71 0.11 27.92 9.10 19.24 Total income 773.16 678.82 13.9% 1,454.59 1,246.62 16.7% 2,582.92 Raw Material 404.76 334.32 776
Slide 8: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (Rs Cr.) Sept-26 Mar-26 Liabilities (Rs Cr.) Sept-26 Mar-26 Non Current Assets Equity Property, Plant and Equipment 1,044.38 1,111.68 Equity Share capital 39.06 39.06 Capital work-in-progress 453.01 297.65 Other Equity 1,536.08 1,373.37 Intangible assets 54.21 7.44
Slide 9: Consolidated Cashflow
Consolidated Cashflow Particulars (Rs. Cr.) H1 FY27 FY26 Net Profit Before Tax 271.92 439.70 Adjustments for: Non Cash Items / Other Investment or Financial Items 86.73 236.03 Operating profit before working capital changes 358.65 675.74 Changes in working capital 85.76 -9.31 Cash generated from/(us
Slide 10: Q2 Performance across years
Q2 Performance across years Total Income EBITDA 773.16 212.49 678.82 182.14 537.27 Rs Cr Rs Cr 462.34 114.66 96.32 QE Sep-23 QE Sep-24 QE Sep-25 QE Sep-26 QE Sep-23 QE Sep-24 QE Sep-25 QE Sep-26 Net Profit EBITDA% PAT% 26.8% 27.5% 117.03 20.8% 21.3% 93.91 15.1% Rs Cr 13.8% % 8.3% 44.66 6.6% 30.51 QE
Slide 11: Annual Performance
Annual Performance Total Income (Rs. In Cr) EBITDA (Rs. In Cr) EBITDA Margin (%) PAT (Rs. In Cr) / Margin (%) 1.31% 5.37% 8.81% 12.68% +17% 2,582.92 2,121.84 25.76% 1,778.53 +48% 665.45 1,629.24 22.35% 327.54 474.16 19.95% +149% 187.00 354.82 12.73% 207.34 95.43 21.28 FY23 FY24 FY25 FY26 FY23 FY24 F
Slide 12: Company Overview
COMPANY OVERVIEW PRIVI SPECIALITY CHEMICALS LIMITED Prosperity With Orderliness
Slide 13: India's Leading Aroma Chemicals Manufacturer
Leading manufacturer, Supplier & Exporter of Aroma Chemicals India's Leading Aroma Chemicals Manufacturer A 30+ year track record of building global leadership in pine- based and speciality aroma chemicals — supplying the world's top fragrance and FMCG companies. 75+ 48,000 MTPA 2 R&D CENTRES 7 40+
Slide 14: Our Journey
Our Journey 2023 2025 2026 Way Forward Crossed turnover of Rs 1,500 Crores Turnover crossed Rs. 2,000 Crores. Turnover crossed Rs. 2,500 Crores. Working on 5K:1K plan Launched Galaxmusk, Camphor and Comissioned and commenced Prionyl. commercial production at PRIGIV 2021 2020 2019 2017 Promoter bough
Slide 15: Geographical Presence
Geographical Presence Manchester Rotterdam Milano Grasse New Jersey Mahad, Maharastra Jhagadia, Gujarat India Shanghai Mexico Singapore 2 Manufacturing 7 Distribution 3 Stocking Serving 40+ Sites Centres Points Countries Disclaimer: This map is a generalised illustration only for the ease of the rea
Slide 16: Competitive Advantages
Competitive Advantages Robust Manufacturing • Privi’s state-of-the-art manufacturing capacities are amongst the largest globally • Manufacturing infrastructure has the best-in-class regulatory compliance & certifications Backward Integration • Integrated inhouse developed CST processing for manufact
Slide 17: PRIGIV — Strategic JV with Givaudan
PRIGIV — Strategic JV with Givaudan PRIGIV Plant at Mahad, MH 51% 49% India's leading manufacturer of aroma Swiss multinational manufacturer of flavours, and fragrance chemicals fragrances and active cosmetic ingredients Globally trusted partner and a preferred World's largest company in the flavour
Slide 18: High R&D focus to develop new products and processes
High R&D focus to develop new products and processes R&D team strength 02 R&D Centers at 117 including scientist, microbiologist & chemistry DSIR recognition for both R&D centres extended till 2029 Mahad and Nerul professionals Synthetic Organic Research lab and Pilot plants are approved by the Depa
Slide 19: Operational Excellence: Driving Efficiency, Quality & Sustainability
Operational Excellence : Driving Efficiency, Quality & Sustainability Safety & People Sustainability R&D & Quality Process Efficiency Asset & Capacity • Regular safety audits • About 70% raw materials • 2 R&D centers (Mahad & Nerul) • Continuous process • Capacity debottlenecking and emergency drill
Slide 20: Growth Strategy
GROWTH STRATEGY PRIVI SPECIALITY CHEMICALS LIMITED Prosperity With Orderliness
Slide 21: Marching towards Vision – 5k | 1k Milestone
Marching towards Vision – 5k | 1k Milestone* New Projects and Products On track to achieve the vision of Rs 5,000 Cr revenue and Rs 1,000 Cr + EBITDA by FY29-30, representing more • Existing products expansion than 2x growth. • Maltol and Ethyl Maltol • Renewable Cyclopentanone • 10+ other High end
Slide 22: Proposed Scheme of Amalgamation
Proposed Scheme of Amalgamation Privi Fine Sciences Private Limited (PFSPL) + Privi Biotechnologies Private Limited (PBPL) + Privi Speciality Chemicals Limited (PSCL) Key Rationale Diverse Product Portfolio Green Science Advantage PFSPL includes Privial, Anethole, and Cyclamen Aldehyde used in fine
Slide 23: Key Growth Levers
Key Growth Levers Existing Product Expansion Expanding the reach of current products China +1 Strategy to increase sales Diversifying supply chains with a focus on China and additional 1 markets 6 New Product Innovation 2 Introducing new products, in synergy with existing raw material Incentive Grow
Slide 24: Key Business Highlights 5k:1k and beyond
Key Business Highlights 5k:1k and beyond Expansion Intellectual Capacity Information Biorefinery In-house talent Projects Property Augmentation Technology Speciality molecule Significant progress in Technology group Privi harnessing in- Flagship product Strengthening its expansion projects scaling b
Slide 25: Thank You
Thank You For further queries, Please contact: Company : Mr. Sanjeev Patil Executive Vice President - Strategy [email protected] www.privi.co.in Investor Relations Advisors : Adfactors PR Pvt. Ltd. Rushabh Shah: [email protected] M: +91 8082180182 Pratik Shah: pratik.shah@adfactorspr.
Privi Speciality Chemicals — Q2 FY27 Earnings Presentation on 6ix